Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Cortical neuron atrophy is a hallmark of depression and includes neurite retraction, dendritic spine loss, and decreased synaptic density. Psychoplastogens, small molecules capable of rapidly promoting cortical neuron growth, have been hypothesized to produce long-lasting positive effects on behavior by rectifying these deleterious structural and functional changes. Here we demonstrate that ketamine and LSD, psychoplastogens from two structurally distinct chemical classes, promote sustained growth of cortical neurons after only short periods of stimulation. Furthermore, we show that psychoplastogen-induced cortical neuron growth can be divided into two distinct epochs: an initial stimulation phase requiring TrkB activation and a growth period involving sustained mTOR and AMPA receptor activation. Our results provide important temporal details concerning the molecular mechanisms by which next-generation antidepressants produce persistent changes in cortical neuron structure, and they suggest that rapidly excreted psychoplastogens might still be effective neurotherapeutics with unique advantages over compounds like ketamine and LSD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their effects seem to be Cmax driven, as very short stimulation periods (15 min−1 h) are sufficient to induce sustained changes in cortical neuron structure (153)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Though the primary molecular targets of ketamine and serotonergic psychedelics are distinct, their downstream pharmacology overlaps, requiring AMPA receptor, TrkB, and mTOR activation to elicit changes in neuronal structure and function (135–137, 148, 153, 154).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [153]
The cited source says what the claim attributes to it.
In the citing paper
“An exceedingly short stimulation period (<1 h) is sufficient for psychoplastogens to activate cortical neuron growth mechanisms that can last for several days (153).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [153]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795
Cited by
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
Vargas, M. V., Dunlap, L. E., Dong, C., Carter, S. J., Tombari, R. J., Jami, S. A., Cameron, L. P., Patel, S. D., Hennessey, J. J., Saeger, H. N., et al. (2023) · Science · doi:10.1126/science.adf0435 · Cited by 489
Self-citationPsychedelics promote plasticity by directly binding to BDNF receptor TrkB
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01316-5 · Cited by 478
The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00192 · Cited by 329
Self-citationTowards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“Other work has shown that a significant neuronal growth phase occurs in the 72 hours after initial exposure to psychedelics [35].”
BackgroundInfluentialThe neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Self-citationNeuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Self-citationA non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Lewis, V., Bonniwell, E. M., Lanham, J. K., Ghaffari, A., Sheshbaradaran, H., Cao, A. B., Calkins, M. M., Bautista-Carro, M. A., Arsenault, E., Telfer, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112203 · Cited by 164
5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines
Cameron, L. P., Patel, S. D., Vargas, M. V., Barragan, E. V., Saeger, H. N., Warren, H. T., Chow, W. L., Gray, J. A., & Olson, D. E. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00718 · Cited by 135
Self-citationBiochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 129
Self-citationPsychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“…psychedelics to researchers, has been shown to increase dendritic growth (Persico et al., 2006; Ohtani et al., 2014; Ly, Greb et al., 2018; Ly et al., 2021), synaptic puncta, spine density (Yoshida et al., 2011; Ly et al., 2018), and spine size (Jones et al., 2009) in cultured cortical…”
Self-citationTherapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
Self-citationJohnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
Self-citationWeiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 74
Clinically relevant acute subjective effects of psychedelics beyond mystical experience
Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00345-6 · Cited by 71
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“Furthermore, both LSD and ketamine activated cortical neuron growth mechanisms after <1 h, an effect which lasted for several days (178) and could be divided into an initial stimulation phase requiring TrkB activation and a growth period involving sustained mTOR and AMPA receptor activation (178).”
BackgroundAgnorelli, C., Spriggs, M. J., Godfrey, K., Sawicka, G., Bohl, B., Douglass, H. M., Fagiolini, A. M., Hashemi, P., Carhart-Harris, R. L., Nutt, D. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106132 · Cited by 68
Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice
Jones, N., Zahid, Z., Grady, S. M., Sultan, Z. W., Zheng, Z., Razidlo, J. A., Banks, M. I., & Wenthur, C. J. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00123 · Cited by 61
Exploring DMT: Endogenous role and therapeutic potential
Schimmelpfennig, J., & Jankowiak-Siuda, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110314 · Cited by 58
Skosnik, P. D., Sloshower, J., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179800 · Cited by 51
The role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 51
Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
Tuck, J. R., Dunlap, L. E., Khatib, Y. A., Hatzipantelis, C. J., Novak, S. W., Rahn, R. M., Davis, A. R., Mosswood, A., Vernier, A. M. M., Fenton, E. M., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416106122 · Cited by 50
Self-citationMagaraggia, I., Kuiperes, Z., & Schreiber, R. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107467 · Cited by 49
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 47
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Urban, M. M., Stingl, M., & Meinhardt, M. W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1156319 · Cited by 46
Engineering Safer Psychedelics for Treating Addiction
Peters, J., & Olson, D. E. (2021) · Neuroscience Insights · doi:10.1177/26331055211033847 · Cited by 45
Self-citationDesouza, L. A., Benekareddy, M., Fanibunda, S. E., Mohammad, F., Janakiraman, B., Ghai, U., Gur, T., Blendy, J. A., & Vaidya, V. A. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.790213 · Cited by 44
The Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 44
Self-citationAarrestad, I. K., Cameron, L. P., Fenton, E. M., Casey, A. B., Rijsketic, D. R., Patel, S. D., Sambyal, R., Johnson, S. B., Ly, C., Viswanathan, J., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02021-1 · Cited by 43
Self-citationKelley, D. P., Venable, K., Destouni, A., Billac, G., Ebenezer, P., Stadler, K., Nichols, C., Barker, S., & Francis, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00660 · Cited by 42
Murray, C. H., Frohlich, J., Haggarty, C. J., Tare, I., Lee, R., & de Wit, H. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01809-2 · Cited by 39
Serotonergic Psychedelics in Neural Plasticity
Łukasiewicz, K., Baker, J. J., Zuo, Y., & Lu, J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.748359 · Cited by 39
The role of serotonin neurotransmission in rapid antidepressant actions
Pehrson, A. L., Roberts, D., Khawaja, A., & McNair, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06098-5 · Cited by 37
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 37
Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression
Borsellino, P., Krider, R. I., Chea, D., Grinnell, R., & Vida, T. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050742 · Cited by 33
Psychedelic therapy in depression and substance use disorders
Korkmaz, N. D., Çıkrıkçılı, U., Akan, M., & Yücesan, E. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16421 · Cited by 32
Psychedelics action and schizophrenia
Maćkowiak, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00546-5 · Cited by 31
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles
Rogers, S. A., Heller, E. A., & Corder, G. F. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01964-9 · Cited by 30
Sapienza, J., Bosia, M., Spangaro, M., Martini, F., Agostoni, G., Cuoco, F., Cocchi, F., & Cavallaro, R. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01721-5 · Cited by 30
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 30
Serotonergic neuromodulation of synaptic plasticity
Higa, G. S. V., Viana, F. J. C., Francis-Oliveira, J., Cruvinel, E., Franchin, T. S., Marcourakis, T., Ulrich, H., & De Pasquale, R. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110036 · Cited by 29
Šabanović, M., Lazari, A., Blanco-Pozo, M., Tisca, C., Tachrount, M., Martins-Bach, A. B., Lerch, J. P., Walton, M. E., & Bannerman, D. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02439-2 · Cited by 28
Preclinical models of treatment-resistant depression: challenges and perspectives
Kolasa, M., & Faron‐Górecka, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00542-9 · Cited by 27
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
Calder, A. E., Hase, A., & Hasler, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02830-z · Cited by 25
Emerging mechanisms of psilocybin-induced neuroplasticity
Sonda, S., Pendin, D., Comai, S., Martin, S. D., Manfredi, P., & Mattarei, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.012 · Cited by 24
Robinson, G. I., Li, D., Wang, B., Zahoruiko, Y., Gerasymchuk, M., Hudson, D., Kovalchuk, O., & Kovalchuk, I. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080427 · Cited by 24
Murphy, R. J., Godfrey, K., Shaw, A. D., Muthukumaraswamy, S. D., & Sumner, R. L. (2024) · BMC Neuroscience · doi:10.1186/s12868-024-00844-5 · Cited by 24
Dahan, J. D. C., Dadiomov, D., Bostoen, T., & Dahan, A. (2024) · npj Mental Health Research · doi:10.1038/s44184-024-00091-w · Cited by 24
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Caspani, G., Ruffell, S., Tsang, W., Netzband, N., Rohani-Shukla, C., Swann, J. R., & Jefferies, W. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107338 · Cited by 21
Psychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 20
Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
Nicholas, C. R. N., Banks, M. I., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R., Hutson, P. R., Sauder, C. J., Dunne, J. D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03059-8 · Cited by 19
Agrawal, R. G., Gillie, D. J., Mungenast, A. E., Chytil, M., Engel, S. R., Wu, M. C., Rasmussen, K., Salinas, E. O., & Olson, D. E. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00667 · Cited by 18
Self-citationPsychedelics, entactogens and psychoplastogens for depression and related disorders
Hoyer, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70088 · Cited by 18
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists
Sharp, T., & Ippolito, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70050 · Cited by 17
Zhornitsky, S., Oliva, H. N. P., Jayne, L. A., Allsop, A. S., Kaye, A. P., Potenza, M. N., & Angarita, G. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1197890 · Cited by 17
Drewko, A. J., Habets, R. L. P., & Brunt, T. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03169-9 · Cited by 16
O’Regan, G., Plummer, Z., Christie, B. R., Shultz, S. R., & Allen, J. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03717-2 · Cited by 15
Ligand-Free Signaling of G-Protein-Coupled Receptors: Physiology, Pharmacology, and Genetics
Sadée, W. (2023) · Molecules · doi:10.3390/molecules28176375 · Cited by 15
Antidepressants enter cells, organelles, and membranes
Blumenfeld, Z., Bera, K., Ċastrén, E., & Lester, H. A. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01725-x · Cited by 15
Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen‐Ducuing, F., David, D. J. P., Poupon, E., Tritschler, L., & Gardier, A. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70038 · Cited by 14
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 14
The Promise of Psychedelic Science
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00071 · Cited by 14
Self-citationClinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 13
van den Berg, M., Magaraggia, I., Schreiber, R., Hillhouse, T. M., & Porter, J. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06106-8 · Cited by 13
Beretta, E., Cuboni, G., & Deidda, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125508 · Cited by 12
Yao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 12
Evidence versus expectancy: the development of psilocybin therapy
Rucker, J. (2023) · BJPsych Bulletin · doi:10.1192/bjb.2023.28 · Cited by 11
Jones, J. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1565852 · Cited by 10
Cortical structural differences following repeated ayahuasca use hold molecular signatures
Mallaroni, P., Mason, N. L., Kloft, L., Reckweg, J. T., van Oorsouw, K. I. M., & Ramaekers, J. G. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1217079 · Cited by 9
van der Heijden, K. V., Zuiker, R. G. J. A., Otto, M. E., Bryan, C. F., Stewart, N., Stillwell, C., de Kam, M. L., van Leuken, M. B., van Gerven, J., & Jacobs, G. E. (2025) · Clinical and Translational Science · doi:10.1111/cts.70234 · Cited by 9
Tuck, J. R., Dunlap, L. E., & Olson, D. E. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c01363 · Cited by 9
Self-citationMicrodosing Psychedelics to Restore Synaptic Density in Schizophrenia
Sapienza, J., Spangaro, M., Comai, S., Sabé, M., Torre, J. T. L., Buonarroti, M., Cavallaro, R., & Bosia, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188949 · Cited by 7
The Key Role of Intracellular 5-HT2A Receptors: A Turning Point in Psychedelic Research?
Sapienza, J. (2023) · Psychoactives · doi:10.3390/psychoactives2040018 · Cited by 7
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury
Plummer, Z., Allen, J., Brand, J., Mayo, L. M., Shultz, S. R., & Christie, B. R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111448 · Cited by 6
Real-Time Analysis of Neuronal Cell Cultures for CNS Drug Discovery
Akere, M. T., Zajac, K. K., Bretz, J. D., Madhavaram, A. R., Horton, A., & Schiefer, I. T. (2024) · Brain Sciences · doi:10.3390/brainsci14080770 · Cited by 6
Allen, J., Sun, M., Baker, T. L., Dames, S., Kryskow, P., Christie, B. R., McDonald, S. J., & Shultz, S. R. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03329-x · Cited by 5
Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model
Kandilakis, C. L., & Papatheodoropoulos, C. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00892 · Cited by 5
Lysergic Acid Diethylamide Alters the Effects of Brain Stimulation in Rodents
Dwiel, L. L., Henricks, A. M., Bragg, E. M., Nicol, J., Gui, J., & Doucette, W. T. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0014 · Cited by 5
Unraveling the Mysteries of Mental Illness With Psilocybin
Sottile, R., Singh, H., Weisman, A., & Vida, T. (2022) · Cureus · doi:10.7759/cureus.25414 · Cited by 5
Psilocybin therapy for depression. A good trip?
Rucker, J. (2023) · Journal of Mental Health · doi:10.1080/09638237.2023.2183492 · Cited by 5
Zhang, J., Lin, C., Lv, X., Zhao, H., & Wang, X. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.02.011 · Cited by 4
Integrated 5-HT2A–TrkB and G protein signaling in serotonergic psychedelic responses
Taddei-Tardon, M., Medina-Rodríguez, L., Maltman, J. L., Hudson, S., Potukanuma, S., Jiménez, J. H., Martin-Guerrero, S. M., González‐Maeso, J., & López‐Giménez, J. F. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03746-6 · Cited by 4
Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
McCulloch, D. E.-W., López, J. P., Dalla, C., Ċastrén, E., Erritzøe, D., Frøkjær, V. G., Lundberg, J., Preller, K. H., Fisher, P. M., & Knudsen, G. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103929 · Cited by 4
Zahid, Z., Sultan, Z. W., Krause, B. M., Wenthur, C. J., Pearce, R. A., & Banks, M. I. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0061 · Cited by 4
Lysergic acid diethylamide induces behavioral changes in Caenorhabditis elegans
Ornelas, I. M., Carrilho, B. D. S., Ventura, M. A. V. D. C., Domith, I., Silveira, C. M. D. V., dos Santos, V. F., Delou, J. M. D. A., Moll, F., Pereira, H. M. G., Junqueira, M., et al. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137903 · Cited by 4
McCoy, K., Reed, F. M., Conn, K., & Foldi, C. J. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.114957 · Cited by 4
Low, Z. X. B., Yong, S. J., AlRasheed, H. A., Al‐Subaie, M. F., Kaabi, N. A., Alfaresi, M. S., Albayat, H., Alotaibi, J., bshabshe, A. A. A. A., Alwashmi, A. S. S., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111279 · Cited by 4
Dahan, A., & Henthorn, T. K. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.991569 · Cited by 4
Boltaev, U., Park, H. W., Brown, K. R., Delgado, M., Wu, J., Diaz-Pacheco, B. N., Botero-Pinzon, M., He, K., Ahern, E., Goldshmid, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.04.583022 · Cited by 4
Cellular mechanisms of serotonergic psychedelics - apical hypercontextualisation
Kaup, K., Jiménez, J. H., & Aru, J. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106876 · Cited by 3
Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs
Ippolito, A., Tiranti, A., Hurley, S., Gilmour, G., Churchill, G. C., & Sharp, T. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00138 · Cited by 3
Noback, M. N., Kenton, J. A., Klein, A. K., Hughes, Z. A., Kruegel, A. C., Schmid, Y., Halberstadt, A. L., & Young, J. W. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110334 · Cited by 3
Vella, Y., Syrová, K., Petrušková, A., Koutrouli, I. R. A., Kútna, V., Pala, J., Nikolič, M., Šíchová, K., Mazoch, V., Jurok, R., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338232 · Cited by 3
Ketamine Pharmacodynamics Entangled: Reply
Dahan, A., Olofsen, E., Henthorn, T. K., van Velzen, M., & Niesters, M. (2022) · Anesthesiology · doi:10.1097/aln.0000000000004350 · Cited by 3
Zhang, C., Wang, Y., & Wang, X. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00379 · Cited by 3
Metadata
- Authors
- Ly, C., Greb, A. C., Vargas, M. V., Duim, W. C., Grodzki, A. C. G., Lein, P. J., & Olson, D. E.
- Affiliations
- University of California, Davis (US)
- Corresponding author
- Olson, David E.
- ORCID
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-09-11
- Volume
- 4
- Issue
- 2
- Pages
- 452-460
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033616
- OpenAlex
- W3086471578
- Cited by
- 123
- References
- 78
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 19 · 2023: 27 · 2022: 13 · 2021: 14 · 2020: 2
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- University of California, Davis
- National Institutes of Health (1S10OD019980-01A1, R01GM128997, T32GM113770, U54 HD079125)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- psychoplastogens, ketamine, LSD, neuronal atrophy, depression, TrkB signaling, mTOR, AMPA receptors, antidepressants, dendritic spine loss, synaptic density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.